{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"}]}],"title":"Any TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"}]}],"title":"Any drug-related TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"title":"Any treatment-emergent serious AE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"A treatment-emergent adverse event (TEAE) is defined as any event arising or worsening after start of study drug administration until the end of the treatment period","groups":[{"description":"Participants received 33 kiloBecquerel (kBq)/kg body weight every 6 weeks for a total of 6 radium-223 dichloride doses in combination with BOR and DEX","id":"OG000","title":"Radium-223 Dichloride 33 kBq/kg + Bortezomib and Dexamethasone"},{"description":"Participants received 55 kBq/kg body weight every 6 weeks for a total of 6 radium-223 dichloride doses in combination with BOR and DEX","id":"OG001","title":"Radium-223 Dichloride 55 kBq/kg + Bortezomib and Dexamethasone"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The safety analysis set including all participants who received at least one administration of study treatment","reportingStatus":"POSTED","timeFrame":"From the start of study drug (radium-223 dichloride) to 30 days after last dose of study treatment (radium-223 dichloride, BOR, or DEX, whichever is last), assessed up to approximately 2 years","title":"Phase 1: The Number of Subjects With Treatment-emergent Adverse Events (TEAEs), Drug-related TEAEs, and Treatment-emergent Serious AE","type":"PRIMARY","unitOfMeasure":"Participants"}